Review Article

What lessons can be learned from the launch of generic clopidogrel?

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 58-68

Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;… Read More »

A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 28-32

Author byline as per print journal: Helle Håkonsen, MScPharm, PhD; Else-Lydia Toverud, MScPharm, PhD Introduction: With a few exceptions, generic drug use has been promoted in western countries by allowing pharmacists to… Read More »

European payer initiatives to reduce prescribing costs through use of generics

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 22-7

Author byline as per print journal:  Brian Godman1,2,3, BSc, PhD; Bjorn Wettermark1,4, MSc, PhD; Iain Bishop5, BSc; Thomas Burkhardt6, MSc; Jurij Fürst7, PhD; Kristina Garuoliene8, MD; Ott Laius9, MScPharm; Jaana E Martikainen10,… Read More »

A patient-centred paradigm for the biosimilars market

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 17-21

Abstract:  The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for… Read More »

Biologicals and biosimilars: a review of the science and its implications

Published in: Volume 1 / Year 2012 / Issue 1
Page: 13-6

Abstract:  Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory… Read More »

A review of generic medicine pricing in Europe

Published in: Volume 1 / Year 2012 / Issue 1
Page: 08-12

Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review… Read More »

Does L-Thyroxine meet the criteria of a narrow therapeutic index drug (NTID) according to Bioequivalence-guideline of the European Medicines Agency?


Aim: This review discusses pros and cons of whether L-Thyroxine should be regarded as a narrow therapeutic Index drug (NTID). Methodology: A search in PubMed was performed in March/April 2014.… Read More »

Protein heterogeneity and the immunogenicity of biotherapeutics

Published in: Volume 7 / Year 2018 / Issue 2

Abstract: High resolution analytical techniques reveal structural micro-heterogeneity within endogenous proteins, however; they are ‘seen’ as ‘self’ molecules by the immune system and immunological tolerance is established. In contrast the… Read More »

In vitro analytical and antibiotic comparison of generic medicine of Moxifloxacin against E. coli and S. aureus bacteria strains

Author(s): , ,

Abstract: Moxifloxacin is a quinolone antibiotic often used to treat infections caused by Gram positive bacteria that have developed resistance in Colombia in recent years. This study was designed to… Read More »

Biocomparable Drugs in Mexico: Challenges and Opportunities in the Treatment of Gaucher Disease

Author(s): , , , , , , , ,

Abstract: Biotechnological drugs are complex molecules, whose manufacturing hinders an identical replication of the original substance; thus, there is not an absolute equivalence between the original drug (innovative) and the… Read More »

Page 4 of 4 « Previous1 2 3 4
Go Back Print